# Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa

> **NCT07489573** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (estimated)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT07489573
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-21
- **Primary completion:** 2029-09-25
- **Final completion:** 2029-11-05
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489573, "Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07489573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*